MMX mesalamine/ mesalazine — Competitive Intelligence Brief

MMX mesalamine/ mesalazine (MMX mesalamine/ mesalazine) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-aminosalicylic acid (5-ASA) agent. Area: Gastroenterology / Immunology.

marketed 5-aminosalicylic acid (5-ASA) agent Prostaglandin and leukotriene synthesis; non-selective anti-inflammatory mechanism Gastroenterology / Immunology Small molecule

Target snapshot

MMX mesalamine/ mesalazine (MMX mesalamine/ mesalazine) — Shire. MMX mesalamine is an anti-inflammatory agent that reduces inflammation in the colon by inhibiting prostaglandin and leukotriene production.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MMX mesalamine/ mesalazine TARGET	MMX mesalamine/ mesalazine	Shire	marketed	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene synthesis; non-selective anti-inflammatory mechanism
Asacol (mesalamine)	Asacol (mesalamine)	University of Washington	marketed	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene synthesis inhibition; free radical scavenging
MMX Mesalamine	MMX Mesalamine	Shire	marketed	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene pathways (topical anti-inflammatory)
sulphasalazine (SSZ)	sulphasalazine (SSZ)	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene synthesis inhibition; NF-κB pathway modulation
Mesalazine(asacol 800 mg)	Mesalazine(asacol 800 mg)	Tehran University of Medical Sciences	marketed	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene synthesis; nuclear factor-kappa B (NF-κB) pathway
Granulated mesalamine	Granulated mesalamine	Bausch Health Americas, Inc.	phase 3	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene synthesis inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-aminosalicylic acid (5-ASA) agent class)

1. Shire · 2 drugs in this class
2. Bausch Health Americas, Inc. · 1 drug in this class
3. Tehran University of Medical Sciences · 1 drug in this class
4. University of Washington · 1 drug in this class
5. Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class